Zde se nacházíte:
Informace o publikaci
PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium
Autoři | |
---|---|
Rok publikování | 2012 |
Druh | Článek v odborném periodiku |
Časopis / Zdroj | Blood |
Fakulta / Pracoviště MU | |
Citace | |
Doi | http://dx.doi.org/10.1182/blood-2012-05-427989 |
Obor | Onkologie a hematologie |
Klíčová slova | GENOME-WIDE ASSOCIATION; RHEUMATOID-ARTHRITIS; FOLLICULAR LYMPHOMA; GERMLINE VARIATION; SUSCEPTIBILITY; TNF; POLYMORPHISMS; NEOPLASMS; APOPTOSIS; LEUKEMIA |
Popis | Many common genetic variants have been associated with non-Hodgkin lymphoma (NHL), but individual study results are often conflicting. To confirm the role of putative risk alleles in B-cell NHL etiology, we performed a validation genotyping study of 67 candidate single nucleotide polymorphisms within InterLymph, a large international consortium of NHL case-control studies. A meta-analysis was performed on data from 5633 B-cell NHL cases and 7034 controls from 8 InterLymph studies. rs3789068 in the proapoptotic BCL2L11 gene was associated with an increased risk for B-cell NHL (odds ratio = 1.21, P random = 2.21 x 10(-11)), with similar risk estimates for common B-cell subtypes. PRRC2A rs3132453 in the HLA complex class III region conferred a reduced risk of B-cell NHL (odds ratio = 0.68, P random = 1.07 x 10(-9)) and was likewise evident for common B-cell subtypes. These results are consistent with the known biology of NHL and provide insights into shared pathogenic components, including apoptosis and immune regulation, for the major B-cell lymphoma subtypes. (Blood. 2012; 120(23):4645-4648) |